The estimated Net Worth of Edward Hu is at least $8.35 million dollars as of 5 June 2020. Mr. Hu owns over 180,000 units of Viela Bio stock worth over $5,201 and over the last 5 years he sold VIE stock worth over $7,952,400. In addition, he makes $390,000 as Independent Director at Viela Bio.
Edward has made over 1 trades of the Viela Bio stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 180,000 units of VIE stock worth $7,952,400 on 5 June 2020.
The largest trade he's ever made was selling 180,000 units of Viela Bio stock on 5 June 2020 worth over $7,952,400. On average, Edward trades about 36,000 units every 0 days since 2019. As of 5 June 2020 he still owns at least 208,059 units of Viela Bio stock.
You can see the complete history of Mr. Hu stock trades at the bottom of the page.
Edward Hu serves as Independent Director of the Company. Mr. Hu is the Co-Chief Executive Officer and director at WuXi AppTec Co., Ltd., or WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. Since August 2007, Mr. Hu has served in various executive management roles at WuXi AppTec, initially as Chief Operating Officer and then as Chief Financial Officer & Chief Investment Officer. In addition, Mr. Hu serves on the board of directors for WuXi Biologics Cayman, Inc., a biologics contract development and manufacturing organization listed on the Hong Kong Stock Exchange. Mr. Hu also serves on the boards of several private biopharmaceutical companies. Mr. Hu earned his B.S. in Physics from Zhejiang University, and his M.S. in Chemistry and MBA from Carnegie Mellon University.
As the Independent Director of Viela Bio, the total compensation of Edward Hu at Viela Bio is $390,000. There are 5 executives at Viela Bio getting paid more, with Zhengbin Yao having the highest compensation of $2,747,550.
Edward Hu is 57, he's been the Independent Director of Viela Bio since 2018. There are 2 older and 9 younger executives at Viela Bio. The oldest executive at Viela Bio, Inc. is Chris Nolet, 63, who is the Independent Director.
Edward's mailing address filed with the SEC is C/O VIELA BIO, INC.,, ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG, MD, 20878.
Over the last 5 years, insiders at Viela Bio have traded over $58,712,400 worth of Viela Bio stock and bought 1,261,091 units worth $24,062,867 . The most active insiders traders include Andreas Wicki, Xiaomeng Tong et Plc Astra Zeneca Uk Ltd Ast.... On average, Viela Bio executives and independent directors trade stock every 41 days with the average trade being worth of $6,348. The most recent stock trade was executed by Aaron Ren on 18 November 2020, trading 2,000 units of VIE stock currently worth $5,680.
Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
Viela Bio executives and other stock owners filed with the SEC include: